APPY talk: is Venaxis's appendicitis test finally set for approval?
This article was originally published in Clinica
Executive Summary
After many setbacks, Venaxis is hopeful that its APPY1 appendicitis test could soon be cleared by the US FDA. The company has just reported what it says are positive top-line results from its pivotal trial: it found a negative predictive value (NPV) of 97%, sensitivity of 97% and specificity of 38%.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.